Lupus Erythematosus, Bullous: Multimedia

References

1. Fujimoto W, Hamada T, Yamada J, Matsuura H, Iwatsuki K. Bullous Systemic Lupus Erythematosus as an Initial Manifestation of SLE. J Dermatol. Dec 2005;32(12):1021-7. [Medline].

2. Roustan G, Salas C, Barbadillo C, Sanchez Yus E, Mulero J, Simon A. Lupus erythematosus with an erythema multiforme-like eruption. Eur J Dermatol. Aug 2000;10(6):459-62. [Medline].

3. Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev. Feb 2006;5(2):160-4. [Medline].

4. Mandelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus?. J Am Acad Dermatol. Apr 2003;48(4):525-9. [Medline].

5. Paradela S, Martinez-Gomez W, Fernandez-Jorge B, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Lupus. 2007;16(9):741-5. [Medline].

6. [Guideline] Finnish Medical Society Duodecim. Systemic lupus erythematosus (SLE). EBM Guidelines. Evidence-Based Medicine. Feb 2007;[Full Text].

7. Ishii N, Yoshida M, Hisamatsu Y, et al. Epidermolysis bullosa acquisita sera react with distinct epitopes on the NC1 and NC2 domains of type VII collagen: study using immunoblotting of domain-specific recombinant proteins and postembedding immunoelectron microscopy. Br J Dermatol. May 2004;150(5):843-51. [Medline].

8. Chen M, Doostan A, Bandyopadhyay P, et al. The cartilage matrix protein subdomain of type VII collagen is pathogenic for epidermolysis bullosa acquisita. Am J Pathol. Jun 2007;170(6):2009-18. [Medline].

9. Woodley DT, Ram R, Doostan A, et al. Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J Invest Dermatol. Jun 2006;126(6):1323-30. [Medline].

10. Chen L, Peterson JD, Zheng WY, Lin SX, Chan LS. Autoimmunity to type VII collagen in SKH1 mice is independent of regulatory T cells. Clin Exp Immunol. Aug 2006;145(2):322-31. [Medline].

11. Chan LS, Lapiere JC, Chen M, et al. Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen. Arch Dermatol. May 1999;135(5):569-73. [Medline].

12. Chen M, Chan LS, Cai X, O'Toole EA, Sample JC, Woodley DT. Development of an ELISA for rapid detection of anti-type VII collagen autoantibodies in epidermolysis bullosa acquisita. J Invest Dermatol. Jan 1997;108(1):68-72. [Medline].

13. Fujii K, Fujimoto W, Ueda M, Makino E, Arata J. Detection of anti-type VII collagen antibody in Sjögren's syndrome/lupus erythematosus overlap syndrome with transient bullous systemic lupus erythematosus. Br J Dermatol. Aug 1998;139(2):302-6. [Medline].

14. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest. May 2006;116(5):1159-66. [Medline].

15. Ting W, Stone MS, Racila D, Scofield RH, Sontheimer RD. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus. 2004;13(12):941-50. [Medline].

16. Khandpur S, Das S, Singh MK. Rowell's syndrome revisited: report of two cases from India. Int J Dermatol. Jul 2005;44(7):545-9. [Medline].

17. Pandhi D, Singal A, Agarwal P. Rowell's syndrome and associated antiphospholipid syndrome. Clin Exp Dermatol. Jan 2004;29(1):22-4. [Medline].

18. Shteyngarts AR, Warner MR, Camisa C. Lupus erythematosus associated with erythema multiforme: does Rowell's syndrome exist?. J Am Acad Dermatol. May 1999;40(5 Pt 1):773-7. [Medline].

19. Zeitouni NC, Funaro D, Cloutier RA, Gagne E, Claveau J. Redefining Rowell's syndrome. Br J Dermatol. Feb 2000;142(2):343-6. [Medline].

20. Gammon WR, Fine JD, Forbes M, Briggaman RA. Immunofluorescence on split skin for the detection and differentiation of basement membrane zone autoantibodies. J Am Acad Dermatol. Jul 1992;27(1):79-87. [Medline].

21. Malcangi G, Brandozzi G, Giangiacomi M, Zampetti M, Danieli MG. Bullous SLE: response to methotrexate and relationship with disease activity. Lupus. 2003;12(1):63-6. [Medline].

22. Alahlafi AM, Wordsworth P, Lakasing L, Davies D, Wojnarowska F. The basement membrane zone in patients with systemic lupus erythematosus: immunofluorescence studies in the skin, kidney and amniochorion. Lupus. 2004;13(8):594-600. [Medline].

23. Alahlafi AM, Wordsworth P, Wojnarowska F. The lupus band: do the autoantibodies target collagen VII?. Br J Dermatol. Mar 2004;150(3):504-10. [Medline].

24. Aydogan K, Karadogan S, Balaban Adim S, Tunali S. Lupus erythematosus associated with erythema multiforme: report of two cases and review of the literature. J Eur Acad Dermatol Venereol. Sep 2005;19(5):621-7. [Medline].

25. Burrows NP, Bhogal BS, Black MM, et al. Bullous eruption of systemic lupus erythematosus: a clinicopathological study of four cases. Br J Dermatol. Mar 1993;128(3):332-8. [Medline].

26. Camisa C, Sharma HM. Vesiculobullous systemic lupus erythematosus. Report of two cases and a review of the literature. J Am Acad Dermatol. Dec 1983;9(6):924-33. [Medline].

27. Daneshpazhooh M, Shahdi M, Aghaeepoor M, Hasiri G, Chams C. A comparative study of antibody titers of blister fluid and serum in patients with subepidermal immunobullous diseases. Int J Dermatol. May 2004;43(5):348-51. [Medline].

28. Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctive but immunologically heterogeneous bullous disorder. J Invest Dermatol. Jan 1993;100(1):28S-34S. [Medline].

29. Gandhi K, Chen M, Aasi S, Lapiere JC, Woodley DT, Chan LS. Autoantibodies to type VII collagen have heterogeneous subclass and light chain compositions and their complement-activating capacities do not correlate with the inflammatory clinical phenotype. J Clin Immunol. Nov 2000;20(6):416-23. [Medline].

30. Gately LE 3rd, Nesbitt LT Jr. Update on immunofluorescent testing in bullous diseases and lupus erythematosus. Dermatol Clin. Jan 1994;12(1):133-42. [Medline].

31. Hall RP, Lawley TJ, Smith HR, Katz SI. Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med. Aug 1982;97(2):165-70. [Medline].

32. Ishikawa O, Zaw KK, Miyachi Y, Hashimoto T, Tanaka T. The presence of anti-basement membrane zone antibodies in the sera of patients with non-bullous lupus erythematosus. Br J Dermatol. Feb 1997;136(2):222-6. [Medline].

33. Kacalak-Rzepka A, Zaluga E, Maleszka R, Krolicki A, Klimowicz A. Bullous systemic lupus erythematosus with antiphospholipid syndrome. J Eur Acad Dermatol Venereol. Jul 2004;18(4):490-4. [Medline].

34. Mutasim DF. Severe subacute cutaneous lupus erythematosus presenting with generalized erythroderma and bullae. J Am Acad Dermatol. Jun 2003;48(6):947-9. [Medline].

35. Penneys NS, Wiley HE 3rd. Herpetiform blisters in systemic lupus erythematosus. Arch Dermatol. Dec 1979;115(12):1427-8. [Medline].

36. Perera GK, Black MM, McGibbon DH. Bullous subacute cutaneous lupus erythematosus. Clin Exp Dermatol. May 2004;29(3):265-7. [Medline].

37. Shirahama S, Furukawa F, Yagi H, Tanaka T, Hashimoto T, Takigawa M. Bullous systemic lupus erythematosus: detection of antibodies against noncollagenous domain of type VII collagen. J Am Acad Dermatol. May 1998;38(5 Pt 2):844-8. [Medline].

38. Tebbe B. Clinical course and prognosis of cutaneous lupus erythematosus. Clin Dermatol. Mar-Apr 2004;22(2):121-4. [Medline].

39. Vassileva S. Bullous systemic lupus erythematosus. Clin Dermatol. Mar-Apr 2004;22(2):129-38. [Medline].

40. Vodegel RM, de Jong MC, Meijer HJ, Weytingh MB, Pas HH, Jonkman MF. Enhanced diagnostic immunofluorescence using biopsies transported in saline. BMC Dermatol. Aug 27 2004;4:10. [Medline].

41. Yang S, Gao Y, Song Y, et al. The study of the participation of basement membrane zone antibodies in the formation of the lupus band in systemic lupus erythematosus. Int J Dermatol. Jun 2004;43(6):420-7. [Medline].

42. Yell JA, Allen J, Wojnarowska F, Kirtschig G, Burge SM. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol. Jun 1995;132(6):921-8. [Medline].

43. Yell JA, Wojnarowska F. Bullous skin disease in lupus erythematosus. Lupus. 1997;6(2):112-21. [Medline].

Further Reading

Keywords

bullous systemic lupus erythematosus, BSLE, bullous eruption of systemic lupus erythematosus, vesiculobullous systemic lupus erythematosus; lupus erythematosus-specific vesiculobullous skin disease, Rowell's syndrome, Rowell syndrome, toxic epidermal necrolysis-like acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus

Contributor Information and Disclosures

Author

Hillary D Johnson-Jahangir, MD, PhD, Staff Physician, Department of Dermatology, Columbia University Medical Center
Hillary D Johnson-Jahangir, MD, PhD is a member of the following medical societies: Medical Society of the State of New York
Disclosure: Nothing to disclose.

Coauthor(s)

Julie V Schaffer, MD, Assistant Professor of Dermatology and Pediatrics, Director of Dermatology Resident Education, Director of Pediatric Dermatology Unit, New York University School of Medicine
Disclosure: Nothing to disclose.

Medical Editor

Kathleen David-Bajar, MD, Former Consultant to the Army Surgeon General, Department of Dermatology, Brooke Army Medical Center
Kathleen David-Bajar, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Pharmacy Editor

Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center
Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Jeffrey P Callen, MD, Professor of Medicine, Chief, Division of Dermatology, University of Louisville School of Medicine
Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and American College of Rheumatology
Disclosure: Amgen Honoraria Consulting; Abbott Honoraria Consulting; Electrical Optical Sciences Honoraria Consulting; Centocor Honoraria Consulting; Genetech Honoraria Consulting; Celgene Honoraria Consulting

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds None; Genentech Consulting fee Consulting; Centocor Consulting fee Consulting; Centocor Grant/research funds None; Covance Consulting fee Consulting; Shire  Consulting

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.